Journal of Medicinal Chemistry p. 1600 - 1606 (1989)
Update date:2022-08-03
Topics:
Smith, Elizabeth M.
Swiss, Gerald F.
Neustadt, Bernard R.
McNamara, Paul
Gold, Elijah H.
et al.
The synthesis of spirapril (5), spiraprilat (25), their RSS stereoisomers, and their glycyl (18b) and lysyl (36, 37) analogues is described.These compounds were evaluated in vivo for inhibition of angiotensin converting enzyme (ACE), and selected compounds were evaluated for in vitro ACE inhibition (spirapril ID50 16 μg/kg; spiraprilat IC50 0.8 nM, ID50 8 μg/kg).In anesthetized rats, iv, esters 5 and 36 are more potent than enalapril, and diacids 25 and 37 are more potent than enalaprilat in vitro.In the conscious rats, orally, 5 and enalapril (2) showed potent and sustained activity at doses of 0.03-1 and 0.1-1 mg/kg, respectively.From this work, spirapril was selected for clinical evaluation as an antihypertensive agent.
View MoreContact:86-15588110016
Address:LINYI CITY,SHANDONG PROVINCE,CHINA
Contact:+86-021-58123769
Address:No.780 of Cailun Road,Zhangjiang Hi-tech Park,Pudong,Shanghai
Contact:+49-9398-993127
Address:Untertorstr. 27
Anhui New Star Pharmaceutical Development Co., Ltd
Contact:013956922763
Address:Floor 3, F9A, F Workshop, No.110 Kexue Road, High-Tech Development Zone, Hefei, Anhui ,China
Contact:+86-13914766747
Address:Floors 21&22, Jin Cheng Tower, No. 216 Middle Longpan Road, Nanjing
Doi:10.1055/s-0039-1690103
(2019)Doi:10.1016/0040-4020(80)80085-8
(1980)Doi:10.1016/j.tet.2004.06.022
(2004)Doi:10.1016/j.steroids.2018.09.010
(2018)Doi:10.1246/bcsj.53.2091
(1980)Doi:10.1039/P19850001725
(1985)